Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug

Toshimitsu Suwaki, Devendra K. Agrawal, Robert G. Townley

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Suplatast tosilate (IPD), a new dimethylsulfonium agent, is used therapeutically in allergic diseases. Suplatast has been reported to attenuate airway hyperresponsiveness in guinea pigs, human IgE synthesis, and murine peritoneal eosinophilia. However, the effect of suplatast on human eosinophils is not known. In this study, we examined the effects of suplatast in human eosinophils on platelet activating factor (PAF, 1 μM)-induced chemotaxis by the blind well chamber technique, eosinophil adhesion to TNF-α (10 ng/ml) or IL-4 (10 ng/ml)-stimulated human umbilical vein endothelial cells (HUVECs), and expression of very late antigen-4 (VLA-4) on eosinophils and vascular cell adhesion molecule-1 (VCAM-1) on HUVECs by flow cytometry. Suplatast suppressed IL-4-induced eosinophil adhesion to HUVECs in a dose-dependent manner. Eosinophils from the normal subjects did not express VLA-4. However, there was a significant increase (P <0.01) in the basal expression of VLA-4 in allergic patients. PAF or IL-4 did not enhance VLA-4 expression on eosinophils, and there was no significant effect of suplatast on VLA-4 expression in allergic patients. Suplatast did not affect TNF-α-induced VCAM-1 expression. Interestingly, suplatast significantly suppressed IL-4 induced VCAM-1 expression on HUVECs and PAF-induced eosinophil chemotaxis. These data suggest that suplatast may modify eosinophil participation in airway inflammation by attenuating inflammatory mediators-induced chemotaxis and adhesion to endothelial cells, and thus might be useful in the treatment of bronchial asthma.

Original languageEnglish
Pages (from-to)2163-2171
Number of pages9
JournalInternational Immunopharmacology
Volume1
Issue number12
DOIs
StatePublished - 2001

Fingerprint

Anti-Allergic Agents
Eosinophils
Integrin alpha4beta1
Human Umbilical Vein Endothelial Cells
Pharmaceutical Preparations
Interleukin-4
Vascular Cell Adhesion Molecule-1
Chemotaxis
suplatast tosilate
Platelet Activating Factor
Eosinophilia
Interleukin-10
Immunoglobulin E
Flow Cytometry
Guinea Pigs
Asthma
Endothelial Cells
Inflammation

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology

Cite this

Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug. / Suwaki, Toshimitsu; Agrawal, Devendra K.; Townley, Robert G.

In: International Immunopharmacology, Vol. 1, No. 12, 2001, p. 2163-2171.

Research output: Contribution to journalArticle

@article{599ac869e9fc4c6b895c809131ee515e,
title = "Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug",
abstract = "Suplatast tosilate (IPD), a new dimethylsulfonium agent, is used therapeutically in allergic diseases. Suplatast has been reported to attenuate airway hyperresponsiveness in guinea pigs, human IgE synthesis, and murine peritoneal eosinophilia. However, the effect of suplatast on human eosinophils is not known. In this study, we examined the effects of suplatast in human eosinophils on platelet activating factor (PAF, 1 μM)-induced chemotaxis by the blind well chamber technique, eosinophil adhesion to TNF-α (10 ng/ml) or IL-4 (10 ng/ml)-stimulated human umbilical vein endothelial cells (HUVECs), and expression of very late antigen-4 (VLA-4) on eosinophils and vascular cell adhesion molecule-1 (VCAM-1) on HUVECs by flow cytometry. Suplatast suppressed IL-4-induced eosinophil adhesion to HUVECs in a dose-dependent manner. Eosinophils from the normal subjects did not express VLA-4. However, there was a significant increase (P <0.01) in the basal expression of VLA-4 in allergic patients. PAF or IL-4 did not enhance VLA-4 expression on eosinophils, and there was no significant effect of suplatast on VLA-4 expression in allergic patients. Suplatast did not affect TNF-α-induced VCAM-1 expression. Interestingly, suplatast significantly suppressed IL-4 induced VCAM-1 expression on HUVECs and PAF-induced eosinophil chemotaxis. These data suggest that suplatast may modify eosinophil participation in airway inflammation by attenuating inflammatory mediators-induced chemotaxis and adhesion to endothelial cells, and thus might be useful in the treatment of bronchial asthma.",
author = "Toshimitsu Suwaki and Agrawal, {Devendra K.} and Townley, {Robert G.}",
year = "2001",
doi = "10.1016/S1567-5769(01)00142-4",
language = "English",
volume = "1",
pages = "2163--2171",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug

AU - Suwaki, Toshimitsu

AU - Agrawal, Devendra K.

AU - Townley, Robert G.

PY - 2001

Y1 - 2001

N2 - Suplatast tosilate (IPD), a new dimethylsulfonium agent, is used therapeutically in allergic diseases. Suplatast has been reported to attenuate airway hyperresponsiveness in guinea pigs, human IgE synthesis, and murine peritoneal eosinophilia. However, the effect of suplatast on human eosinophils is not known. In this study, we examined the effects of suplatast in human eosinophils on platelet activating factor (PAF, 1 μM)-induced chemotaxis by the blind well chamber technique, eosinophil adhesion to TNF-α (10 ng/ml) or IL-4 (10 ng/ml)-stimulated human umbilical vein endothelial cells (HUVECs), and expression of very late antigen-4 (VLA-4) on eosinophils and vascular cell adhesion molecule-1 (VCAM-1) on HUVECs by flow cytometry. Suplatast suppressed IL-4-induced eosinophil adhesion to HUVECs in a dose-dependent manner. Eosinophils from the normal subjects did not express VLA-4. However, there was a significant increase (P <0.01) in the basal expression of VLA-4 in allergic patients. PAF or IL-4 did not enhance VLA-4 expression on eosinophils, and there was no significant effect of suplatast on VLA-4 expression in allergic patients. Suplatast did not affect TNF-α-induced VCAM-1 expression. Interestingly, suplatast significantly suppressed IL-4 induced VCAM-1 expression on HUVECs and PAF-induced eosinophil chemotaxis. These data suggest that suplatast may modify eosinophil participation in airway inflammation by attenuating inflammatory mediators-induced chemotaxis and adhesion to endothelial cells, and thus might be useful in the treatment of bronchial asthma.

AB - Suplatast tosilate (IPD), a new dimethylsulfonium agent, is used therapeutically in allergic diseases. Suplatast has been reported to attenuate airway hyperresponsiveness in guinea pigs, human IgE synthesis, and murine peritoneal eosinophilia. However, the effect of suplatast on human eosinophils is not known. In this study, we examined the effects of suplatast in human eosinophils on platelet activating factor (PAF, 1 μM)-induced chemotaxis by the blind well chamber technique, eosinophil adhesion to TNF-α (10 ng/ml) or IL-4 (10 ng/ml)-stimulated human umbilical vein endothelial cells (HUVECs), and expression of very late antigen-4 (VLA-4) on eosinophils and vascular cell adhesion molecule-1 (VCAM-1) on HUVECs by flow cytometry. Suplatast suppressed IL-4-induced eosinophil adhesion to HUVECs in a dose-dependent manner. Eosinophils from the normal subjects did not express VLA-4. However, there was a significant increase (P <0.01) in the basal expression of VLA-4 in allergic patients. PAF or IL-4 did not enhance VLA-4 expression on eosinophils, and there was no significant effect of suplatast on VLA-4 expression in allergic patients. Suplatast did not affect TNF-α-induced VCAM-1 expression. Interestingly, suplatast significantly suppressed IL-4 induced VCAM-1 expression on HUVECs and PAF-induced eosinophil chemotaxis. These data suggest that suplatast may modify eosinophil participation in airway inflammation by attenuating inflammatory mediators-induced chemotaxis and adhesion to endothelial cells, and thus might be useful in the treatment of bronchial asthma.

UR - http://www.scopus.com/inward/record.url?scp=0034779885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034779885&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(01)00142-4

DO - 10.1016/S1567-5769(01)00142-4

M3 - Article

VL - 1

SP - 2163

EP - 2171

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 12

ER -